Merck & Co., Inc.





Market Closed - Nyse 01:30:04 13/07/2024 am IST 5-day change 1st Jan Change
127.7 USD -0.96% Intraday chart for Merck & Co., Inc. +1.01% +17.16%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Mixed Premarket Friday MT
Sector Update: Health Care MT
Merck: completes acquisition of EyeBio CF
Merck Completes Eyebiotech Acquisition MT
Immutep Achieves 'Positive' Results From Cohort B of Phase 2B Cancer Trial; Shares Rise Pre-Bell MT
Merck & Co., Inc. completed the acquisition of Eyebiotech Limited. CI
Morgan Stanley Adjusts Price Target on Merck to $134 From $132 MT
Merck: acquires aquatics division of Elanco Animal Health CF
Merck's Animal Health Division Completes $1.3 Billion Acquisition of Elanco Animal Health's Aqua Business MT
Prelude Therapeutics Inks Deal With Merck for Phase 2 Study to Evaluate its SMARCA2 Degrader With Keytruda MT
Stocks to watch as Biden and Trump vie for presidency RE
Merck, Orion Convert Ongoing Collaboration Into Exclusive Global License for Opevesostat MT
Merck: license agreement with Orion Corp. for opevesostat CF
Merck, Orion Convert Collaboration Into Exclusive License DJ
Orion Corporation and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell Top 200 Value Index CI
Merck & Co., Inc.(NYSE:MRK) added to Russell 1000 Dynamic Index CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000 Value Index CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 1000 Value-Defensive Index CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 1000 Value Index CI
Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000E Value Index CI
Merck: positive opinion for Winrevair in Europe CF
Merck Gets CHMP Backing of Winrevair in Pulmonary Arterial Hypertension DJ
Merck Says European Medicines Agency's Committee Recommends Approval of Heart Disease Drug Winrevair MT
Merck Receives Positive EU CHMP Opinion for WINREVAIR (Sotatercept) in Pulmonary Arterial Hypertension CI
Chart Merck & Co., Inc.
More charts
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
127.8 USD
Average target price
142.6 USD
Spread / Average Target
1st Jan change Capi.
+17.16% 32TCr
+62.66% 85TCr
+40.93% 64TCr
-4.37% 36TCr
+9.87% 30TCr
+14.94% 25TCr
+4.62% 23TCr
+18.60% 23TCr
+14.86% 18TCr
+0.45% 16TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck & Co., Inc.
  5. Sector Update: Health Care Stocks Retreat Wednesday Afternoon